Infectious Agents and Cancer | |
COVID-19 vaccination is associated with enhanced efficacy of anti-PD-(L)1 immunotherapy in advanced NSCLC patients: a real-world study | |
Research | |
Zhuxian Zhu1  Ziqiang Zhang2  Yunfei Qian3  Yin-Yuan Mo4  | |
[1] Department of Nephrology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China;Department of Respiratory and Critical Care Medicine, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Pudong Hospital of Fudan University, Shanghai, China;Department of Respiratory and Critical Care Medicine, Tongji University School of Medicine, Shanghai, China;Institute of Clinical Medicine, Zhejiang Provincial People’s Hospital of Hangzhou Medical College, Hangzhou, China; | |
关键词: COVID-19 vaccination; Immune checkpoint inhibitor (ICI); Non-small cell lung cancer (NSCLC); Progression-free survival (PFS); Overall survival (OS); | |
DOI : 10.1186/s13027-023-00526-7 | |
received in 2023-06-10, accepted in 2023-08-28, 发布年份 2023 | |
来源: Springer | |
【 摘 要 】
BackgroundCoronavirus disease 2019 (COVID-19) vaccine has played a major role in ending the pandemic. However, little is known about the influence of COVID-19 vaccine on the efficacy of immunotherapy in patients with non-small cell lung cancer (NSCLC).ObjectivesThe goal of this study is to explore whether COVID-19 vaccine impacts the efficacy of immune checkpoint inhibitors (ICIs) in NSCLC patients.MethodsWe retrospectively analyzed the survival data of ICI-treated 104 patients with stage III–IV NSCLC, who either received COVID-19 vaccination (n = 25) or no vaccination (n = 79). The potential risk factors, in particular roles of COVID-19 vaccination in the efficacy of ICIs in these patients, were evaluated.ResultsOur results showed significantly improved ORR (28.0% vs. 11.39%, p = 0.05) and DCR (88.0% vs. 54.43%, p = 0.005) in the COVID-19 vaccinated group compared with the non-vaccinated group. Regarding the long-term survival benefits, COVID-19 vaccine showed profound influence both on the PFS (HR = 0.16, p = 0.021) and OS (HR = 0.168, p = 0.019) in patients with NSCLC under ICIs treatment. The PFS (p < 0.001) or OS (p < 0.001) was significantly improved in the COVID-19 vaccinated group, compared with the non-vaccinated group. Moreover, CD4 T cell (p = 0.047) level was higher in the COVID-19 vaccinated group than in the non-vaccinated group.ConclusionsCOVID-19 vaccination enhances anti-PD-1 immunotherapy efficacy in patients with stage III–IV NSCLC, suggesting that COVID-19 vaccination may provide additional benefit to NSCLC patients.
【 授权许可】
CC BY
© BioMed Central Ltd., part of Springer Nature 2023
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202310110568550ZK.pdf | 1225KB | download | |
13690_2023_1170_Article_IEq29.gif | 1KB | Image | download |
MediaObjects/40345_2023_311_MOESM1_ESM.docx | 32KB | Other | download |
Fig. 4 | 1554KB | Image | download |
【 图 表 】
Fig. 4
13690_2023_1170_Article_IEq29.gif
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
- [36]
- [37]
- [38]
- [39]